2nd Quarter - Report

CROSSROADS STRATEGIES, LLC for GENENTECH, INC.

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S.959, Pharmaceutical Compounding Quality and Accountability Act; H.R.1416, Cancer Patient Protection Act of 2013; S.957, Drug Supply Chain Security Act; H.R.1919, Safeguarding America's Pharmaceuticals Act of 2013; compounding issues; pharma supply chain issues; Medicare reimbursement issues.

LobbyistCovered position, as disclosed
ANNE BRADY —
JOHN GREEN —
STEWART HALL —
MATHEW LAPINSKI —
HUNTER MOORHEAD —
STEVE TILTON —
TODD MATTHEW WEISS —
MATT WISE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 959 (113th), H.R. 1416 (113th), S. 957 (113th), H.R. 1919 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.